血浆血栓调节蛋白水平与缺血性卒中:一项基于人群的预后队列研究
该多中心预后队列纳入3532例中国缺血性卒中患者,随访3个月。血浆血栓调节蛋白最高四分位与主要结局风险降低相关(OR 0.75,95%CI 0.59-0.97),mRS分布显著改善,提示血栓调节蛋白可能具有保护作用,但需在不同人群中进一步验证。
要点
- 血浆血栓调节蛋白最高四分位者3个月死亡和主要残疾复合结局风险降低(OR 0.75)。
- 最高四分位者主要残疾风险降低(OR 0.73),血管事件风险无显著差异(OR 0.80)。
- 血栓调节蛋白水平越高,mRS评分分布改善越显著(p trend=0.005)。
核心结论
- 基线血浆血栓调节蛋白水平升高与缺血性卒中后3个月不良临床结局风险降低相关,提示血栓调节蛋白在缺血性卒中发生发展中可能具有保护作用。
- 作者指出需要来自不同人群的进一步研究来重复验证这些发现。
研究设计与样本
- 多中心预后队列研究,纳入来自中国急性缺血性卒中抗高血压试验的3532例中国缺血性卒中患者,随访至发病后3个月。
主要发现
- 3个月随访期间,867例患者发生主要结局。
- 多因素调整后,血浆血栓调节蛋白最高四分位与主要结局的校正OR为0.75(95%CI 0.59-0.97;p趋势=0.029)。
- 最高四分位与主要残疾的校正OR为0.73(95%CI 0.56-0.94;p趋势=0.028)。
- 最高四分位与血管事件的校正OR为0.80(95%CI 0.42-1.51;p趋势=0.232)。
- 血栓调节蛋白四分位越高,mRS评分分布改善越显著(p趋势=0.005)。
局限性
- 作者指出需要来自不同人群的进一步研究来重复验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Thrombomodulin has been suggested to be implicated in ischemic stroke because of its anticoagulant, anti-inflammatory, and cytoprotective properties. We aimed to investigate the associations of plasma thrombomodulin levels with clinical outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS: Our multicenter prognostic cohort study included 3,532 Chinese ischemic stroke patients from the China Antihypertensive Trial in Acute Ischemic Stroke. All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale [mRS] score ≥3) at 3 months after ischemic stroke. Secondary outcomes included major disability (mRS score 3-5), vascular events, and the ordered 7-level categorical score of the mRS. RESULTS: During 3 months of follow-up, 867 participants experienced the primary outcome. After multivariate adjustment, the adjusted odds ratios or hazard ratios associated with the highest quartile of plasma thrombomodulin were 0.75 (95% CI 0.59-0.97; p trend = 0.029) for the primary outcome, 0.73 (95% CI 0.56-0.94; p trend = 0.028) for major disability, and 0.80 (95% CI 0.42-1.51; p trend = 0.232) for vascular events. In addition, a significantly better shift in the distribution of the mRS score was observed with higher thrombomodulin quartiles (p trend = 0.005). A multivariable-adjusted spline regression model showed a linear relationship between plasma thrombomodulin and the risk of primary outcome (p for linearity = 0.027). Subgroup analyses further confirmed these associations. DISCUSSION: Increased plasma thrombomodulin levels at baseline were associated with decreased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting a protective role of thrombomodulin in the development of ischemic stroke. Further studies from various populations are needed to replicate our findings.
引用
- Zhu Z, Guo D, Jia Y, et al. Plasma Thrombomodulin Levels and Ischemic Stroke: A Population-Based Prognostic Cohort Study. Neurology. 2022. PMID: 35654592. doi:10.1212/WNL.0000000000200783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。